Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

1999 Publications

  1. Walters, D.L., D.L. Jacobs, J.E. Tomaszewski and S.Graves 1999. Analysis of Various Neucleosides in Plasma Using Solid Phase Extraction and High-Performance Liquid Chromatography with UV Detection. J. Pharm. Biomed. Anal., 19, 955-965.
  2. Mirsalis, J.C., J. Schindler-Horvat, J.R. Hill, J.E. Tomaszewski, C.A. Tyson and S.J. Donohue, 1999. Toxicity of Dolastatin 10 in Mice, Rats and Dogs and its Clinical Relevance. Cancer Chemother Pharmacol. 44(5):395-402.
  3. Sim, B.K.L., Fogler, W.E., Zhou, X.H., Liang, H., Madsen, J.W., Luu, K., O'Reilly, M.S., Tomaszewski, J.E., Fortier, A.H., 1999. Zinc Ligand-Disrupted Recombinant Human Endostatin: Potent Inhibition of Tumor Growth, Safety and Pharmacokinetic Profile. Angiogenesis 3: 41-51.
  4. Walker, D.L., Reid, J.M., Svingen, P.A., Rios, R., Covey, J.M., Alley, M.C., Hollingshead, M.G., Budihardjo, I.I., Eckdahl, S., Boerner, S., Kaufmann, S.H., Ames, M.M., 1999. Murine Pharmacokinetics of 6-Aminonicotinamide (NSC 21206), A novel Biochemical Modulating Agent, Biochem. Pharmacol., 58: 1057-1066.
  5. Egorin, M.J., Z.-M. Yuan, D.L. Sentz, K. Plaisance and J.L. Eiseman, 1999. Plasma Pharmacokinetics of Butyrate after Intravenous Administration of Sodium Butyrate or Oral Administration of Tributyrin or Sodium Butyrate to Mice and Rats. Cancer Chemother. Pharmacol., 43: 445-453.
  6. Egorin, M.J., E.G. Zuhowski, D.L. Sentz, J.M. Dobson, P.S. Callery and J.L. Eiseman, 1999. Plasma Pharmacokinetics and Tissue Distribution in CD2F1 Mice of Pc4 (NSC 676418), a Silicone Phthalocyanine Photodynamic Sensitizing Agent. Cancer Chemother. Pharmacol., 44: 283-294.
  7. Gao, H., Huang, K.-C., Yamasaki, E.F., Chan, K.K., Chohan, L., Snapka, R.M., 1999. XK469, a Selective Topoisomerase II Poison. PNAS, 96: 12168-12173.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov